

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

FVIII

RRID:NSRRC_0018

Type: Organism

Proper Citation

RRID:NSRRC_0018

Organism Information

URL: <https://nsrrc.missouri.edu/StrainAvail/>

Proper Citation: RRID:NSRRC_0018

Description: Application: Hemophilia Research

Species: Sus scrofa

Notes: Application: Hemophilia Research

Phenotype: Production of FVIII, SERPINA1 and FURIN in the milk

Affected Gene: FVIII, FURIN, SERPINA1

Genomic Alteration: Transgenes: Human coagulation factor VIII, Human alpha 1-antitrypsin, Propeptide cleavage enzyme (PACE/FURIN)

Catalog Number: 18

Background: outbred

Database: NSRRC, National Swine Resource and Research Center (NSRRC)

Database Abbreviation: NSRRC

Organism Name: FVIII

Record Creation Time: 20230226T235432+0000

Record Last Update: 20260829T225921+0000

Ratings and Alerts

No rating or validation information has been found for FVIII.

No alerts have been found for FVIII.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: NSRRC, National Swine Resource and Research Center (NSRRC)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Zhang K, et al. (2023) Ex vivo factor VIII-modified proliferating human hepatocytes therapy for haemophilia A. Cell proliferation, 56(5), e13467.

Sihn CR, et al. (2022) Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers. Molecular therapy. Methods & clinical development, 24, 142.

Shi Q, et al. (2022) A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD. Blood advances, 6(9), 2778.

Zhang L, et al. (2022) Young mice administered adult doses of AAV5-hFVIII-SQ achieve therapeutic factor VIII expression into adulthood. Molecular therapy. Methods & clinical development, 26, 519.

Wang D, et al. (2021) Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B. Clinical and translational medicine, 11(3), e375.

Zhang X, et al. (2020) Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Science advances, 6(34).

Cao W, et al. (2020) Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency. Molecular therapy. Methods & clinical development, 19, 486.

Delignat S, et al. (2020) Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. Frontiers in immunology, 11, 393.

Garcia J, et al. (2020) A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9. Research and practice in thrombosis and haemostasis, 4(1), 64.

Pigoli C, et al. (2019) Bleaching melanin in formalin-fixed and paraffin-embedded melanoma specimens using visible light: a pilot study. European journal of histochemistry : EJH, 63(4).

Chen H, et al. (2019) Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. *Scientific reports*, 9(1), 16838.

Taves S, et al. (2019) Hemophilia A and B mice, but not VWF-/-mice, display bone defects in congenital development and remodeling after injury. *Scientific reports*, 9(1), 14428.

Loomans JI, et al. (2018) Desmopressin in moderate hemophilia A patients: a treatment worth considering. *Haematologica*, 103(3), 550.

Noonan SA, et al. (2018) Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment. *Oncotarget*, 9(12), 10536.

Bunting S, et al. (2018) Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice. *Molecular therapy : the journal of the American Society of Gene Therapy*, 26(2), 496.

Schenk B, et al. (2018) Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial. *Thrombosis journal*, 16, 1.

Slatter DA, et al. (2018) Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. *JCI insight*, 3(6).

Korth-Bradley J, et al. (2018) Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A. *Clinical and translational science*, 11(3), 283.

Mandoj C, et al. (2018) Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. *Journal of translational medicine*, 16(1), 129.

Rayes J, et al. (2018) Complement C3 is a novel modulator of the anti-factor VIII immune response. *Haematologica*, 103(2), 351.